Shockwave IVL + DES (Shockwave DES)

Physician-Initiated PMCF Trial Investigating Shockwave Intravascular Lithotripsy and a Drug Eluting Vascular Stent System Deployment for Heavily Calcified Femoropopliteal Disease

The objective of this clinical investigation is to evaluate, in a controlled setting, the 12 months safety and efficacy of the combination of Shockwave Intravascular Lithotripsy and a polymer coated Drug Eluting Stent device, for PACSS 3 and PACSS 4 calcified femoropopliteal disease.

Study Overview

• Status: Recruiting
• Conditions: Peripheral Arterial Disease; Superficial Femoral Artery Stenosis; Calcifications Vascular
• Intervention / Treatment: Device: Peripheral lithotripsy system (Shockwave Medical)

• Study Type: Observational
• Enrollment (Estimated): 50

Contacts and Locations

• Study Contact: Name: Annelena Held-Wehmöller, PhD; Phone Number: +4915785128140; Email: shockwave_des@fcre.eu

Study Locations

• Germany
  • Arnsberg, Germany
    • Recruiting
    • Klinikum Hochsauerland
    • Contact: Michael Lichtenberg, MD
  • Essen, Germany
    • Recruiting
    • University Hospital Essen
    • Contact: Christos Rammos, MD
  • Hamburg, Germany
    • Recruiting
    • University Hospital Eppendorf
    • Contact: Erwin Blessing, MD
  • Karlsbad, Germany
    • Recruiting
    • SRH Klinikum Karlsbad-Langensteinbach
    • Contact: Ralph Oberacker, MD
  • Lünen, Germany
    • Not yet recruiting
    • St. Marien Hospital
    • Contact: Martin Schröder, MD
  • Munich, Germany
    • Recruiting
    • University Hospital LMU Munich
    • Contact: Konstantinos Stavroulakis, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 21 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Patient population for this study are patients with a diminished blood flow in their heavily calcified femoropopliteal lesions, who need a reintervention.

Description

Inclusion Criteria:

• Subject must be between 21 and 85 years old
• Clinical diagnosis of symptomatic peripheral artery disease, defined by Rutherford Becker Classification score 3-5
• Willing to comply with the specified follow-up evaluation
• Written informed consent prior to any study procedures

• Stenotic, restenotic after PTA or occlusive lesion(s) located in the native Superficial Femoral Artery (SFA) and/or proximal Popliteal Artery (PPA):

  1. Degree of stenosis ≥ 70% by visual agiographic assessment
  2. Vessel diameter ≥ 4 and ≥ 6 mm
  3. Total lesion length (or series of lesions) ≥ 30 mm and 210 mm (Note: Lesion segment(s) must be filly covered with one or two overlapping DES stent (s) be fully covered with one or two overlapping DES stent(s)
  4. Target lesion located at least three centimeters above the inferior edge of the femur
• Severity of calcification PACSS 3-4
• Patent infrapopliteal and popliteal artery; i.e. single vessel runoff or better with at least one of three vessels patent (>50% stenosis) to the ankle or foot with no planned intervention.
• Study entry after successful target lesion crossing of the guidewire (guidewire located intraluminally or subintimally); Both crossing devices as well as retrograde recanalization can be used.
• Non-target lesion interventions to restore adequate blood flow, in the same index procedure are allowed. This intervention must be prior to the treatment of the study lesion and should be completed successfully.

Exclusion Criteria:

• Not treated ipsilateral significant (>50%) stenosis of the iliac arteries
• Non severely calcified disease (absence of calcification, PACSS 1, PACSS 2)
• Significant (>50%) stenosis of all infrapopliteal arteries, no patent artery to the foot
• Angiographic evidence of thrombus within the target vessel
• Thrombolysis within 72 hours prior to the index procedure
• Previously stented target lesion / vessel
• Subjects who have undergone prior surgery of the target lesion SFA/PPA to treat atherosclerotic disease
• Bypass Anastomosis stenosis
• Concomitant hepatic insufficiency, thrombophlebitis, deep venous thrombus, coagulation disorder or receiving immunosuppressant therapy
• Recent MI or stroke <30 days prior to the index procedure
• Life expectancy less than 24 months
• Known or suspected active infection at the time of the index procedure
• Known or suspected major allergies or contraindications to aspirin, clopidogrel bisulfate (Plavix) and ticlopidine (Ticlid), heparin, or contrast agent
• Any significant medical condition which, in the investigator's opinion, may interfere with the subject's optimalparticipation in the study
• The subject is currently participating in another drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study
• Female subjects pregnant, breastfeeding, of childbearing potential who are planning to become pregnant in the next 5 years.
• End-stage-renal disease
• Presence of Severe Ischemic Ulcers or frank gangrene (Rutherford class 6).

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Heavily calcified femoropopliteal disease; Subject must be between 21 and 85 years old; Clinical diagnosis of symptomatic peripheral artery disease, defined by Rutherford Becker Classification score 3-5; Willing to comply with the specified follow-up evaluation; Written informed consent prior to any study procedures	Device: Peripheral lithotripsy system (Shockwave Medical); The combination of Shockwave Intravascular Lithotripsy and a polymer coated Drug Eluting Stent device for calcified femoropopliteal disease.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Primary Patency	Defined as a target lesion without a hemodynamically significant stenosis on duplex ultrasound (>50%, systolic velocity ratio no greater than 2.4) and without Target Lesion Revascularization (TLR)	12 months
Procedural success:	Defined as technical success and completion of the procedure without complications , meaning successful treatment of the vessels (technical success) in the absence of: vessel rupture or perforation that require an intervention; need for emergency surgical revascularization of target limb; symptomatic thrombus or distal emboli that require surgical, mechanical, or pharmacologic means to improve flow and extend hospitalization; unplanned above the ankle amputation; major adverse cardiovascular events (defined as composite of total death, myocardial infarction, coronary revascularization and stroke).	30 days post procedure

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Primary Patency	Defined as a target lesion without a hemodynamically significant stenosis on duplex ultrasound (>50 systolic velocity ratio no greater than 2,4) and without Target Lesion Revascularization (TLR)	6 months
Target Lesion Revascularization (TLR)	Defined as the need for target lesion revascularization after index procedure.	6- and 12-months
Secondary Patency Rate	Defined as restored flow in the treated segment after occlusion or restenosis.	6- and 12-months
Amputation-free Survival rate	Defined as the time until a major amputation of the index limb and/or death of any cause, whichever occurred first.	6- and 12-months
Major Amputation Rate	Defined as any aboveankle amputation.	6- and 12-months
Clinical Success	Defined as an improvement of the Rutherford Becker Classification of one class or more, as compared to the preprocedure Rutherford Becker Classification.	6- and 12-months
Absence of Major Adverse Events (MAE)	Acute Coronary Syndrome, Stroke, Death, Major Amputation or TLR.	6- and 12-months

Collaborators and Investigators

• Sponsor: Dr. Sabrina Overhagen
• Investigators: Principal Investigator: Konstantinos Stavroulakis, MD, Vascular Department, LMU Munich

Study record dates

Study Major Dates

• Study Start (Actual): July 22, 2022
• Primary Completion (Estimated): July 1, 2024
• Study Completion (Estimated): October 1, 2024

Study Registration Dates

• First Submitted: November 21, 2021
• First Submitted That Met QC Criteria: March 21, 2022
• First Posted (Actual): March 22, 2022

Study Record Updates

• Last Update Posted (Actual): July 6, 2023
• Last Update Submitted That Met QC Criteria: July 4, 2023
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Metabolic Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Atherosclerosis; Calcium Metabolism Disorders; Calcinosis; Peripheral Arterial Disease; Peripheral Vascular Diseases; Vascular Calcification
• Other Study ID Numbers: FCRE-210505

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No